SG11201803581VA - Chimeric RSV, Immunogenic Compositions, and Methods of Use - Google Patents
Chimeric RSV, Immunogenic Compositions, and Methods of UseInfo
- Publication number
- SG11201803581VA SG11201803581VA SG11201803581VA SG11201803581VA SG11201803581VA SG 11201803581V A SG11201803581V A SG 11201803581VA SG 11201803581V A SG11201803581V A SG 11201803581VA SG 11201803581V A SG11201803581V A SG 11201803581VA SG 11201803581V A SG11201803581V A SG 11201803581VA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- immunogenic compositions
- chimeric rsv
- rsv
- chimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562247962P | 2015-10-29 | 2015-10-29 | |
| US201662334547P | 2016-05-11 | 2016-05-11 | |
| PCT/US2016/058976 WO2017075125A1 (en) | 2015-10-29 | 2016-10-27 | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803581VA true SG11201803581VA (en) | 2018-05-30 |
Family
ID=58630734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803581VA SG11201803581VA (en) | 2015-10-29 | 2016-10-27 | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11235050B2 (en) |
| EP (1) | EP3368547A4 (en) |
| JP (2) | JP7311872B2 (en) |
| KR (1) | KR20180085730A (en) |
| CN (1) | CN108602858A (en) |
| BR (1) | BR112018008708A2 (en) |
| CA (1) | CA3003726A1 (en) |
| MX (1) | MX2018005462A (en) |
| SG (1) | SG11201803581VA (en) |
| WO (1) | WO2017075125A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3798310A1 (en) | 2013-03-14 | 2021-03-31 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| CN115947873A (en) | 2017-04-04 | 2023-04-11 | 华盛顿大学 | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and uses thereof |
| EP3758747A1 (en) | 2018-02-28 | 2021-01-06 | University of Washington | Self-asssembling nanostructure vaccines |
| CR20210306A (en) * | 2018-11-13 | 2021-07-22 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
| US20220324917A1 (en) * | 2021-04-12 | 2022-10-13 | Sk Bioscience Co., Ltd. | Recombinant rsv live vaccine strain and the preparing method thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| IL105456A (en) | 1992-04-21 | 1996-12-05 | American Home Prod | Attenuated respiratory syncytial virus vaccine compositions |
| AT401526B (en) | 1993-02-10 | 1996-09-25 | Scheirer Winfried | REAGENT SOLUTION TO STABILIZE LUMINESCENCE IN LUCIFERASE MEASUREMENT |
| ES2210273T5 (en) | 1994-07-18 | 2010-03-29 | Conzelmann, Karl-Klaus, Prof. Dr. | VIRUS WITH NEGATIVE CHAIN NON-SEGMENTED RECOMBINANT INFECTIVE. |
| US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
| US6689367B1 (en) | 1995-09-27 | 2004-02-10 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| US6713066B1 (en) | 1996-07-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
| US7846455B2 (en) | 1996-07-15 | 2010-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated chimeric respiratory syncytial virus |
| US7485440B2 (en) | 1995-09-27 | 2009-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
| AU727923B2 (en) | 1995-09-27 | 2001-01-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
| US6923971B2 (en) | 1995-09-27 | 2005-08-02 | The United States Of America As Represented By The Department Of Health & Human Services | Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes |
| US6214805B1 (en) | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| BRPI9710363B8 (en) | 1996-07-15 | 2021-07-06 | Us Gov Health & Human Serv | attenuated recombinant respiratory syncytial virus (rsv) particle, vaccine to induce protection against recombinant respiratory syncytial virus (rsv), expression vector, and method of producing an infectious recombinant respiratory syncytial virus (rsv). |
| US6699476B1 (en) | 1996-07-15 | 2004-03-02 | Peter L. Collins | Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| US6074859A (en) | 1997-07-08 | 2000-06-13 | Kikkoman Corporation | Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein |
| US20040005542A1 (en) | 2001-06-22 | 2004-01-08 | Krempl Christine D | Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes |
| US20020018780A1 (en) * | 2000-05-25 | 2002-02-14 | Scott Koenig | Epitope-based vaccine for respiratory syncytial virus F-protein |
| DE602004027362D1 (en) | 2003-03-28 | 2010-07-08 | Medimmune Llc | COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320 |
| ES2670713T3 (en) | 2003-12-24 | 2018-05-31 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Respiratory syncytial virus with a complementary genomic deficiency in trans |
| CA2587084C (en) | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
| WO2008133663A2 (en) | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Codon modified immunogenic compositions and methods of use |
| US9476032B2 (en) | 2007-03-30 | 2016-10-25 | The Research Foundation For The State University Of New York | Attenuated viruses useful for vaccines |
| AU2009311287C1 (en) | 2008-11-05 | 2015-02-19 | Merck Sharp & Dohme Corp. | Live, attentuated respiratory syncytial virus |
| US10227569B2 (en) | 2011-04-12 | 2019-03-12 | Emory University | Respiratory syncytial virus expression vectors |
| DK3275892T3 (en) * | 2011-05-13 | 2020-04-06 | Glaxosmithkline Biologicals Sa | PRÆFUSIONS-RSV F ANTIGENS |
| US9492525B2 (en) | 2011-07-06 | 2016-11-15 | Nanobio Corporation | Human respiratory syncytial virus vaccine |
| US8816081B2 (en) | 2012-08-06 | 2014-08-26 | Basf Se | Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells |
| CA2900713A1 (en) | 2013-02-08 | 2014-08-14 | Steffen Mueller | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
| WO2014160463A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prefusion rsv f proteins and their use |
| US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| EP3798310A1 (en) | 2013-03-14 | 2021-03-31 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| US9060975B2 (en) * | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
-
2016
- 2016-10-27 BR BR112018008708A patent/BR112018008708A2/en active Search and Examination
- 2016-10-27 JP JP2018522569A patent/JP7311872B2/en active Active
- 2016-10-27 EP EP16860742.2A patent/EP3368547A4/en active Pending
- 2016-10-27 US US15/772,275 patent/US11235050B2/en active Active
- 2016-10-27 KR KR1020187014777A patent/KR20180085730A/en not_active Application Discontinuation
- 2016-10-27 SG SG11201803581VA patent/SG11201803581VA/en unknown
- 2016-10-27 CN CN201680072681.XA patent/CN108602858A/en active Pending
- 2016-10-27 WO PCT/US2016/058976 patent/WO2017075125A1/en active Application Filing
- 2016-10-27 CA CA3003726A patent/CA3003726A1/en active Pending
- 2016-10-27 MX MX2018005462A patent/MX2018005462A/en unknown
-
2022
- 2022-01-14 US US17/575,829 patent/US20230293660A1/en active Pending
-
2023
- 2023-04-13 JP JP2023065428A patent/JP2023100654A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11235050B2 (en) | 2022-02-01 |
| JP7311872B2 (en) | 2023-07-20 |
| BR112018008708A2 (en) | 2018-11-06 |
| MX2018005462A (en) | 2018-08-01 |
| CA3003726A1 (en) | 2017-05-04 |
| EP3368547A4 (en) | 2019-06-05 |
| JP2023100654A (en) | 2023-07-19 |
| JP2019500320A (en) | 2019-01-10 |
| WO2017075125A1 (en) | 2017-05-04 |
| CN108602858A (en) | 2018-09-28 |
| US20180333477A1 (en) | 2018-11-22 |
| KR20180085730A (en) | 2018-07-27 |
| US20230293660A1 (en) | 2023-09-21 |
| EP3368547A1 (en) | 2018-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192145T1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| HK1254525A1 (en) | Therapeutic compositions, combinations, and methods of use | |
| IL251527A0 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| PL3557998T3 (en) | Compouns, compositions and methods of use | |
| HUE054694T2 (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201803581VA (en) | Chimeric RSV, Immunogenic Compositions, and Methods of Use | |
| GB201610599D0 (en) | Immunogenic Composition | |
| PL3373910T3 (en) | Echinomycin formulation, method of making and method of use thereof | |
| PT3552017T (en) | Compounds, compositions and methods | |
| GB201711635D0 (en) | Immunogenic composition | |
| IL256833A (en) | Il-17f-specific capture agents, compositions, and methods of using and making | |
| GB201711637D0 (en) | Immunogenic composition | |
| HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201705085UA (en) | Polymer composition, its method of preparation, its use and composition comprising it | |
| IL252683B (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| GB201614485D0 (en) | Immunogenic composition | |
| RO130539B8 (en) | Herbicidal composition, preparation process and use thereof | |
| GB201604755D0 (en) | Immunogenic compositions | |
| HK1258765A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
| GB201513614D0 (en) | Compositions, compounds and methods and uses relating thereto | |
| IL260206A (en) | Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof | |
| IL254597A0 (en) | Crystalline form of ahu377, preparation method and use thereof | |
| HK1231496A1 (en) | Chagasin-based scaffold compositions, methods, and uses chagasin | |
| HK1259196A1 (en) | Delayed-release formulations, methods of making and use thereof |